Entrada Therapeutics, Inc.

As of August 6, 2025, Entrada Therapeutics, Inc. is considered risky and overvalued with a high P/E ratio of 13, a low price to book value of 0.76, negative EV to EBITDA and EV to EBIT ratios, and a year-to-date stock performance of -67.9% compared to the S&P 500's 12.22% return.

As of May 8, 2025, Entrada Therapeutics, Inc. is considered attractive and undervalued with a P/E ratio of 13 and a Price to Book Value of 0.76, despite a year-to-date stock performance decline of 59.28%, contrasting with the S&P 500's 2.44% gain.

As of June 18, 2025, Entrada Therapeutics, Inc. has a bearish technical stance with moderate strength, driven by daily moving averages, monthly MACD, and Bollinger Bands indicating bearish signals, despite a mildly bullish weekly KST and significant underperformance compared to the S&P 500.

Entrada Therapeutics, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, with recent net sales of $21 million and a net profit of -$17 million. It has a market cap of $273.64 million and key metrics include a P/E ratio of 13.00 and a return on equity of 5.94%.

As of Jun 18, Entrada Therapeutics, Inc. has a market capitalization of 273.64 million and reported net sales of 172.22 million and net profit of 24.78 million over the latest four quarters.